Browse Articles
Discover research articles across all indexed journals
Lewis Y antigen as a novel target for CAR (chimeric antigen receptor) T-cell therapy in patients with neuroendocrine prostate cancer.
217 Background: Neuroendocrine prostate cancers (NEPC) currently have no effective therapies. While CAR (Chimeric Antigen Receptor) T cell therapies targeting PSMA and PSCA receptors are currently in phase 1/2 studies in metastatic castrate-resistant prostate cancer (mCRPC), antigen targets for NEPC remain limited. Lewis Y antigen (LeY) is an oncofetal antigen expressed only in adult tumour cells and is considered a target for CAR T cell therapy in haematological, lung, ovarian and colon cancer. We previously found that LeY is a promising target for CAR T cell therapy in prostate cancer and that preconditioning LeY-directed CAR T cells with carboplatin further enhances tumour responses in mCRPC. We investigated if LeY can be used as a novel CAR T cell target for NEPC. Methods: The expression of the Lewis Y antigen was assessed in our patient-derived prostate cancer xenograft collection using immunohistochemistry (IHC). To assess the efficacy of LeY-CAR T cells, we used specimens established from a patient (Patient 508) with NEPC who had incurable metastatic disease and failed standard treatments. We generated CAR T cells from his peripheral blood mononuclear cells (PBMCs) to test their specificity and efficacy in vitro against established cell lines. Results: In our MURAL PDX collection of 59 prostate tumours, 81% (9/11) NEPCs expressed LeY antigen on IHC. Next, we successfully produced anti-LeY CAR T cells from the patient’s PBMCs using retroviral transduction. Flow cytometry verified efficient transduction of the CAR constructs. Previous studies found that a 1:1 ratio of CD4 + :CD8 + T cells improved outcomes following CAR T cell therapy 5,6 , so we further phenotyped patient T cells by flow cytometry. The CD4 + :CD8 + T cell ratio was nearly 1:1 (51.7% and 41.4% of total T cells, respectively). Next, we used an immunobead assay to investigate CAR-T specificity in releasing proinflammatory cytokines. Significant cytokine production was observed after a 4-hour co-culture with LeY+ human ovarian cancer cell line, OVCAR3, vs co-culture with control LeY- MDA-MB435 cells (p=0.0004), demonstrating the specificity of the CAR T cells.Lastly, we showed that patient CAR T cells effectively killed LeY+ cells (OVCAR3), but not control LeY- cells (MDA-MB435; p<0.0001). Tumour cell death was measured by the amount of released chromium following 16-hour co-culture. CAR T cells killed LeY+ target cells more effectively than their non-transduced equivalents at a range of effector-to-target ratios, with up to 15-fold increase in cell death. Conclusions: Our preclinical studies show that most NEPC tumors express the LeY antigen and that patient-derived CAR T cells specifically kill those cells. These findings identified a potential CAR T treatment target for NEPC for a phase 1/2 study.
Real-world community oncology-based treatment patterns for first line axitinib plus pembrolizumab in advanced renal cell carcinoma: Initial dosing, dose reductions and clinical outcomes.
487 Background: Axitinib (AXI) with pembrolizumab (PEM) is approved for first line (1L) treatment of advanced renal cell carcinoma (aRCC). This study provides real-world evidence of treatment patterns and outcomes in 1L aRCC patients treated in primarily community practice settings. Methods: This retrospective, multicenter, community oncologist-based chart review study used the Cardinal Health Oncology Provider Extended Network (OPEN). Patients with age ≥18 years, stage IV clear cell aRCC diagnosis, 1L AXI+PEM initiation between 22-Apr-2019 to 22-Feb-2024, and ≥6 months follow-up were included. Descriptive statistics were used to report demographics and treatment patterns. Duration of therapy (rwDOT) was defined as start date to discontinuation date of 1L AXI+PEM (any cause). Progression-free survival (rwPFS) was defined as start of 1L AXI+PEM to physician-reported progression or death. Results: Physicians (n=25) abstracted data for 300 patients, who were a median age of 66.7 years (interquartile range [IQR]: 60.0-72.8), 61.0% (n=183) male, 69.3% (n=208) White, and 11.3% (n=34) with sarcomatoid features. International Metastasis RCC Database Consortium risk groups for patients were 18.0% favorable, 59.3% intermediate, and 21.7% poor risk (n=3 unknown). Median follow-up overall was 12.3 (IQR: 8.1-21.6) months. Most patients (95%; n=285) started AXI at the initial recommended dose of 5 mg twice daily (BID; Table). Few patients (14.3%; n=43) required AXI dose reductions, with a median time to first AXI dose reduction of 2.3 months (IQR: 1.4-3.7), while 8.7% (n=26) of patients were able to dose escalate (7.3% [n=22] to 7 mg BID; 1.3% [n=4] to 10 mg BID). At data collection, 44.7% (n=134) of patients had discontinued AXI+PEM (78.7% due to progression; 7.8% due to adverse events). Median rwDOT of 1L AXI+PEM was 11.7 (IQR: 7.0-18.5) months and 12-month rwPFS was 74.3% (95% confidence interval: 68.3-79.4). Conclusions: This is one of the first comprehensive studies to describe real-world treatment patterns and clinical outcomes of 1L AXI+PEM for aRCC patients in the US community setting. The majority of patients were able to start 1L AXI+PEM at the FDA-recommended initial dose, with a minority of patients requiring dose reductions. Further prospective studies investigating the impact of 1L AXI+PEM treatment modification on clinical outcomes for aRCC are needed. Initial AXI regimen: 5 mg orally BID (n, %) 285, 95.0 Time from 1L initiation to first AXI decrease (months; median, IQR) 2.3, 1.4-3.7 Time from 1L initiation to first AXI increase (months; median, IQR) 0.5, 0.5-2.8 AXI dose/frequency after first decrease (n, %) 43, 14.3 3 mg orally BID 36, 83.7 2 mg orally BID 6, 14.0 Other ( 2 mg BID, 2 weeks on 1 week off) 1, 2.3 AXI dose/frequency after first increase (n, %) 26, 8.7 7 mg orally BID 22, 84.6 10 mg orally BID 4, 15.4
A natural language processing algorithm to extract MRI and biopsy-related phenotypes for prostate cancer patients.
356 Background: Extraction of data from unstructured medical records is a powerful but challenging tool for deriving novel information to drive research, improve clinical care and better inform guidelines. Here, we describe the creation and validation of a novel natural language processing (NLP) algorithm for extracting components of interest from biopsy and MRI reports for prostate cancer patients. Our algorithm specifically extracts the Gleason score from biopsy reports and maximum Prostate Imaging-Reporting and Data System (PI-RADS) score, Prostate-specific androgen (PSA) density, prostate volume, and prostate dimensions from MRI reports. Methods: MRI and biopsy pathology reports were extracted for a cohort of 155,570 patients diagnosed with prostate cancer between 1999 and 2024 either in the VA Cancer Registry System (VACRS) with prostate as their primary site of tumor or in the VA Corporate Data Warehouse with a relevant procedure or diagnosis code. These were annotated by a physician and a trained research scientist to generate data for the development and validation of our algorithm. Disagreements between annotators were adjudicated by a urologist. Our rule-based NLP algorithm was iteratively developed on 600 annotated and unannotated notes. The algorithm was validated on a manually annotated set of 250 MRI reports and 250 biopsy pathology notes from 378 patients at 78 VA centers for procedures between 2004 and 2024. Precision (true positives / (true positives + false positives)), recall (true positives / (true positives + false negatives)), and F1 score (2 * (precision * recall) / (precision + recall)) were computed to evaluate algorithm performance, with higher scores indicating better performance. Results: Our algorithm successfully extracted all five components from text reports with high precision and sensitivity. Item-level performance metrics for our algorithm on unseen data are reported in the table below. Post-hoc spot checking of algorithm performance on an additional sample of notes selected by procedure year revealed consistency of results across time for all components except prostate dimensions, for which a greater proportion of recent negative notes were false negatives. Further error analysis showed that many Gleason scores that our algorithm did not extract were repetitions of scores successfully extracted elsewhere in the note. Conclusions: Our NLP algorithm is able to derive structured data from medical reports with highly diverse formats with excellent accuracy and reliability. This approach has great potential to facilitate data extraction in a range of settings and to drive future research and clinical questions. Component Precision % Recall % F1 score % Gleason grade group 99.1 94.7 96.9 PI-RADS 95.5 92.7 94.1 PSA density 100.0 99.0 99.5 Prostate volume 96.9 94.5 95.7 Prostate dimensions 98.4 90.2 94.1
Evaluating the combined role of HHLA2 and PD-L1 as biomarkers in first-line nivolumab therapy in advanced clear cell renal cell carcinoma.
598 Background: PD-1 directed immune checkpoint inhibitors are effective in many tumor types, including kidney cancers. HHLA2 is a negative immune checkpoint, generally expressed on PD-L1 negative clear cell renal cell carcinomas (ccRCC) (Bhatt, et al. 2021). Therapeutics targeting either HHLA2 or its inhibitory receptor KIR3DL3 are in Phase I trials and predictive biomarkers are needed to help direct treatment. We previously reported that efficacy of nivolumab correlated with tumor PD-L1 status in patients with kidney cancer treated in the first line setting (GU16- 260; Atkins, et al. 2022). We hypothesize that HHLA2 expression in combination with PD-L1 expression may provide a clinically significant biomarker for resistance to PD-1 blockade in patients with advanced ccRCC. Methods: HHLA2 expression in tumor cells (TC) was assessed by immunohistochemistry coupled with image analysis algorithms in 63 pre-treatment primary ccRCC tissues from patients enrolled in the HCRN GU16-260 trial. TC PDL-1 positivity had been previously evaluated in this cohort (Atkins, 2022). TC HHLA2 expression in combination with TC PD-L1 expression was correlated with progression-free survival (PFS) and objective response rate (ORR). Results: Consistent with our prior reports, HHLA2 expression did not overlap with PD-L1 expression on tumor cells. TC HHLA2 expression in combination with TC PD-L1 expression identified three groups of patients with different clinical outcomes with regards to ORR (trend test p-value = 0.016) and PFS (trend test p-value = 0.024) (Table). Patients with positive (>0%) TC PD-L1 expression had the best outcomes (ORR=62.5%, median PFS=24.7 months); patients with negative TC PD-L1 expression and low (<61%) TC HHLA2 expression had intermediate outcomes (ORR=38.5%, median PFS=10.6 months) and patients with negative TC PD-L1 expression and high (≥61%) TC HHLA2 expression had the worst outcomes (ORR=12.5%, median PFS=3.5 months). Conclusions: Further investigation of the HHLA2/PD-L1 combined biomarker is warranted as it may be helpful in identifying patients that do not respond to anti-PD-1 therapy but could benefit from agents targeting the HHLA2/KIR3DL3 pathway. HHLA2 and PDL-1 category Number of patients(63 total) ORR PFS (median, months) TC PD-L1 >0% 16 62.5% 24.7 TC PD-L1 = 0% & TC HHLA2 <61% (low) 39 38.5% 10.6 TC PD-L1 = 0% & TC HHLA2 ≥61% (high) 8 12.5% 3.5 Trend test p-value 0.016 0.024
Survival disparities by race in advanced urothelial carcinoma (aUC): A real-world analysis.
668 Background: Retrospective population data suggest poorer survival for non-White aUC patients. However, data on survival disparities in the era of immuno- and targeted therapies is limited. Methods: This cohort study used Flatiron Health’s nationwide de-identified electronic health record (EHR)-derived database. 7,244 patients (pts) were identified. Pts who started systemic therapy for aUC from 1/1/2017 to 5/1/2024 and had a recorded race were included. Baseline demographics, including social determinants of health (SDOH) score, performance status (PS), disease characteristics, treatment history, and clinical outcomes were abstracted. Progression free survival (PFS) and overall survival (OS) were compared between Black, White and Asian patients via Kaplan-Meier log-rank analysis and Cox proportional hazards models. Independent sample t-tests and chi-square analyses were used for univariate comparisons. P-values < 0.05 were considered statistically significant. Results: A total of 2,388 pts with aUC were identified, with 1.4% Asian, 5.2% Black, 14.4% “other,” and 78.9% White. In 1L, 17.9% received immunotherapy (IO) monotherapy, 4.2% received enfortumab vedotin + pembrolizumab (EVP), 37.5% received carboplatin-based regimens (carbo), 27.8% cisplatin-based regimens (cis), and 12.5% other chemotherapy (p=0.317). ECOG PS>1 at diagnosis was associated with non-White race (p=0.022). Black patients received treatment at an academic center (41.0%) more often than White patients (25.6%; p<0.001). Black pts had lower SDOH score compared White (p<0.001). Asian (HR0.73, p=0.3) and Black (HR1.07, p=0.3) pts had similar PFS to White pts, as well as similar OS with HR0.85(p=0.4) and HR1.05(p=0.4), respectively. On Cox univariate analysis, there was no significant 1L PFS difference between White, Asian, and Black pts on cis (n=665, p=0.3), carbo (n=895, p=0.7), EVP (n= 25, p=0.8), or IO (n=428, p=0.3). OS was not significantly different by race for any 1L therapy. Conclusions: In a large real-world database, race did not affect overall aUC survival. Baseline characteristics and survival by race. Black (n=124) White (n=1884) Asian (n=33) Other (n=344) Sig (p) Baseline Characteristics ECOG PS 0-1 (%) 55.5 64.6 58.2 62.1 0.027 2-4 (%) 18.5 15.5 19.4 15.2 Academic treatment center (%) 36.6 25.9 13.4 13.2 <0.001 Mean SDOH score (0-5) 2.27 3.26 3.38 2.97 <0.001 1L Treatment IO (%) 23.8 16.4 20.0 17.5 0.317 EVP (%) 5.7 3.9 4.4 4.0 Carbo (%) 32.9 36.5 37.4 38.0 Cis (%) 27.4 29.2 27.8 29.8 Other (%) 10.2 14.0 10.4 10.7 Survival 1L mPFS (m) 5.2 4.6 5.1 4.2 0.300 mOS (m) 5.3 6.9 8.7 5.2 0.400 Sig values (p<0.05) in bold.
ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic alterations (GAs).
808 Background: Erdafitinib (E) is an approved treatment in patients with mUCwith FGFR 3 GAs after progression on platinum-based chemotherapy (PBC). Enfortumab Vedotin (EV) is approved to treat patients with mUC following prior PBC and PD1/L1 inhibitors or as First-line therapy in combination with pembrolizumab. Retrospective studies suggest that the activity of EV is not compromised by FGFR 3/2 GAs. EV and erdafitinib have different mechanisms of activity and toxicities are mostly non-overlapping. Hence, there is rationale to evaluate the feasibility of combination EV and E, to overcome the difficulties of resistance and sequencing agents in mUC patients with FGFR 3/2 GAs. Methods: This is an ongoing, single arm, multicenter, Phase I, 3+3 design dose-escalation and expansion study of E+ EV combination evaluating the safety, tolerability, PK, and antitumor activity in patients with mUC harboring FGFR3/2 GAs who have progressed after platinum and/or PD1/L1 inhibitor therapies. Dose escalation phase aims to identify the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of EV in combination with fixed dose of E at 8 mg/day (table). Results: As of data cutoff, 9 patients were enrolled and completed dose limiting toxicity (DLT) period (1 st cycle) in the dose-escalation phase. Six patients were enrolled at DL1 with 1 DLT (skin rash) and 3 at DL2 (no DLT). The most common all grade treatment-related adverse events (TRAEs) included hyperphosphatemia (88%), mucositis (88%), high AST (88%), hypercalcemia (75%), palmar plantar erythrodysesthesia (75%), peripheral neuropathy (75%), alopecia (63%), diarrhea (63%), hypoalbuminemia (63%) and hypomagnesemia (63%). Grade 3 TRAEs included palmar plantar erythrodysesthesia (50%), anemia (17%), rash (17%), anorexia (17%) and paronychia (17%). One patient developed grade 4 Stevens-Johnson syndrome related to EV which subsequently improved. PK data are available for all 6 patients in DL1. The average steady-state Cmin of E and MMAE was 1430 ± 639 ng/mL and 1.4 ± 0.9 ng/ml, respectively, and the average Cmax of MMAE was 3.9 ± 0.9 ng/mL at DL1. All 9 patients are evaluable with 100% best objective rate, including 8 partial responses (PRs) and 1 complete response (CR). The mOS was NR (95% 17.1 months-NR), mPFS was 7.52 months (95% CT 5.55-NR) with median follow up of 22.7 months. The mDOR is 5.49 months. The RP2D of EV is 1.25 mg/kg in combination with E at 8 mg/day. Conclusions: E+EV combination is feasible and preliminarily exhibits promising antitumor activity. Dose expansion is ongoing at RP2D dose of EV with E. Clinical trial information: NCT04963153 . Dose Level (DL) Dose Cycle Length E EV Level -1 8 mg PO QD 0.75 mg/kg IV (maximum dose 75 mg) D1,8,15 28 days Level 1 8 mg PO QD 1 mg/kg IV (maximum dose 100 mg) D1,8,15 Level 2 8 mg PO QD 1.25 mg/kg IV (maximum dose 125 mg) D1,8,15
First-in-human phase 0 safety, imaging, pharmacokinetics, and dosimetry study of <sup>64</sup> Cu-PD-32766, a carbonic anhydrase IX (CAIX)-targeting peptide, in patients with clear cell renal cell carcinoma (ccRCC).
TPS605 Background: Carbonic Anhydrase (CA)IX is a type of carbonic anhydrase and is expected to be a useful target for detecting tumors with poor prognosis. Particularly in clear cell renal cell carcinoma, high CAIX expression has been reported in a large proportion of patients. In this study, we developed a novel radioligand agent called PD-32766 that specifically binds to CAIX and administered it to recurrent cases of clear cell renal cell carcinoma (ccRCC) patient. Safety, imaging, pharmacokinetics and dosimetry are evaluated. Methods: Between May 2024 and September 2024, PD-32766 labeled by positron-emitting 64Cu (64Cu-PD-32766) was intravenously administered at a dose of 148 MBq (±20%) to five patients with clear cell renal cell carcinoma who had either distant metastasis or local recurrence, and who met other eligibility criteria. PET/CT imaging was performed at 5, 60, 120, 240 minutes, 24, and 48 hours after administration, with vital signs, blood tests, and urinalysis performed as needed. The primary endpoint was the patient-level PET uptake positivity rate of target tumor regions. Secondary endpoints included the number of positive lesions, pharmacokinetics, estimated radiation dose, and the frequency and types of adverse events. This trial is registered under the jRCT trial identifier:jRCTs031240046. Results: 64Cu-PD-32766 demonstrated good tolerability, with no serious complications observed. The average patient-level PET uptake positivity rate at 120 minutes was 75%. The average lesion-level PET positivity rate was 96.2%. Tumor uptake was highest at 60, 120 minutes post-administration. The effective dose for whole body was 0.102±0.036 mSv/MBq. The stomach and small intestine had the highest absorbed doses among all organs, with 0.712±0.287 mGy/MBq and 0.304±0.067 mGy/MBq, respectively. Conclusions: 64Cu-PD-32766 demonstrated an excellent positivity rate in ccRCC patients with no significant adverse events and tolerated radiation dose to normal organs, proving high diagnostic capability and suggesting future therapeutic uses by labeling with therapeutic radionuclides. Clinical trial information: jRCTs031240046 .
Immune profiling at the single-cell level to evaluate the immune microenvironment in bladder cancer: Insights from non-muscle invasive and muscle-invasive disease.
842 Background: Advanced Bladder Cancer (BC) presents significant challenges due to its high incidence and limited treatment options. Most patients initially present with non-muscle invasive bladder cancer (NMIBC), managed with transurethral resection (TURBT) and Bacillus Calmette–Guerin (BCG) therapy. However, some cancers recur or develop resistance, progressing to muscle-invasive bladder cancer (MIBC), which is associated with high mortality and limited curative options. While radical cystectomy (RC) is the standard treatment for MIBC, it has considerable morbidity. Thus, there is a critical need for predictive tools to guide treatment decisions and novel therapeutic approaches. Immunotherapies show promise, but their efficacy remains constrained. Analyzing the immune infiltrate in BC may uncover mechanisms of resistance and identify new targets. Methods: We investigated the immune microenvironment in NMIBC and MIBC using high-dimensional single-cell analysis, including scRNAseq and Imaging Mass Cytometry (Cytomass). Tumor tissues were obtained from BC patients who underwent cystectomy or Trans urethral removal of bladder tumour (TURBT). We enrolled 7 NMIBC and 8 MIBC patients for scRNAseq, isolating CD45+ immune cells and CD45- epithelial and stromal cells using FACS. The samples were processed with 10X technology to reveal transcriptional landscapes. Additionally, we enrolled 5 NMIBC and 5 MIBC patients for Cytomass analysis, where tissue sections were snap-frozen, stained, and analyzed with the Hyperion system. Our primary endpoint was to identify differences in the composition of tumor and immune cells between NMIBC and MIBC. The study was funded by the Next Generation EU Plan - Piano Nazionale di Ripresa e Resilienza (PNRR-MAD-2022-12376756). Results: The cohort included 15 patients with clinically significant BC who underwent radical cystectomy or TURBT. scRNAseq analysis of patients revealed differences in immune cell abundance and activation states between NMIBC and MIBC samples, identifying distinct cell types and high intra-tumoral heterogeneity. Notable changes were observed tumor-infiltrating B cell lymphocytes, with different abundance in tumors depending on the cell subsets. Immature B cells were enriched in MIBC when compared to NMIBC, indicating a potential role in tumor progression. Cytomass analysis further highlighted modulations in immune cell activation and spatial localization between NMIBC and MIBC. Conclusions: Our findings demonstrate the utility of single-cell RNA sequencing in elucidating the immune landscape of BC and highlight significant immune changes between MIBC and NMIBC. This data enhances our understanding of immune composition and the role of specific immune subsets in BC, potentially informing clinical risk stratification and treatment decision-making.
Disease management costs and healthcare resource utilization by progression health state among patients with previously untreated locally advanced or metastatic urothelial cancer.
714 Background: Significant disease management cost (DMC) burden and healthcare resource utilization (HRU) have been reported for patients with advanced bladder cancer; however, available data were outdated. We estimated the real-world DMC and HRU for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) receiving first-line (1L) treatment over time and by progression health state with more contemporary data. Methods: Patients aged ≥65 years with la/mUC receiving 1L treatment were identified from the SEER-Medicare linked database (2007–2019 [SEER]; 2007-2020 [Medicare]). Disease progression on 1L treatment was defined as the initiation of second-line treatment or the diagnosis of secondary malignancies. All-cause DMC and HRU were evaluated for all eligible patients during the pre-progression period, defined as the time from 1L initiation to date of progression or end of follow-up. For patients who progressed after 1L treatment, DMC and HRU were also assessed during the post-progression period, defined as the time from date of progression to end of follow-up. DMC were calculated as the sum of all-cause medical costs (inpatient [IP] + emergency room [ER] + outpatient [OP] costs + other medical costs not associated with these settings [e.g., skilled nursing facility]) and pharmacy (Rx) + drug administration costs, excluding the Rx and drug administration costs of la/mUC treatments. HRU included IP, ER, and OP visits, and use of radiation therapy and imaging. Costs and HRU were summarized on a per-patient per-month (PPPM) basis and stratified by time intervals: 0 to <12 months, 12 to <24 months, and 24+ months. All costs were inflated to 2023 US dollars. Results: Among the 1,145 patients with la/mUC who received 1L treatment, 872 (76.2%) progressed after 1L treatment. DMC (PPPM) post-progression were higher compared to pre-progression across all time intervals ($12,039 vs. $8,422 [0 to < 12 months], $5,994 vs. $3,119 [12 to <24 months], and $4,591 vs $1,743 [24+ months]) and decreased over successive time intervals for both pre- and post-progression health states. Similar findings in HRU indicate higher number of IP and OP visits in the post-progression state, except for OP visits during the 0 to <12 months interval. ER visits were similar in all but the 24+ months interval, where higher rates in the post-progression state were observed. Use of radiation therapy and imaging was higher in all intervals in the post-progression health state. Conclusions: DMC for la/mUC patients receiving 1L therapy were higher in the post-progression state compared with the pre-progression health state. The highest costs and HRU incurred within the first 12 months of 1L treatment initiation and disease progression. Contemporary time-varying DMC during progression health states is valuable to assess economic impact of new therapies.
Efficacy of nivolumab plus ipilimumab in T1aN0M0 renal cell carcinoma (RCC) patients: Results from 3-year follow-up of the phase 2 pilot study.
536 Background: Some patients with primary renal cell carcinoma (RCC) are not candidates for surgery or nephron-sparing interventions due to various factors, such as the presence of a functional single kidney with a central, high-complexity tumor. This study aimed to evaluate whether a combination of nivolumab and ipilimumab could eliminate the primary tumor in patients with T1aN0M0 RCC. Methods: This prospective, multicenter, phase 2 pilot study enrolled patients with biopsy-confirmed clear-cell RCC (cT1a) ≤4 cm, no metastases, and who were ineligible for surgery or nephron-sparing procedures. Patients were treated with ipilimumab (1 mg/kg) every 3 weeks for four doses, alongside nivolumab (240 mg) every 2 weeks for eight doses. The primary endpoint was the complete response rate. Simon's two-stage design was used, testing the null hypothesis of a true complete response rate of 11%. A type I error rate of 0.05 and a power of 0.9 were set, with the null hypothesis rejected if 3 or more responses were observed in 8 patients. Results: From February 2020 to June 2021, 8 patients were enrolled, with a median age of 77.9 years (range 73–89). The cohort was entirely Caucasian, predominantly male (75%), and 62.5% had centrally located tumors. Six patients had moderate to severe comorbidities. All patients completed the immunotherapy without experiencing grade ≥2 adverse events. After a median follow-up of 37.4 months (95% CI 31.7–44.5), no complete responses were observed. However, partial responses were seen in 4 patients (50%), with continued tumor reduction after therapy. The median tumor size decreased from 3.11 cm (range 2.2–3.9) to 1.89 cm (range 1.1–4.0). Tumor shrinkage was observed in 6 patients (75%), while 1 patient experienced a slight tumor enlargement (+0.5 cm, +13%) after 9 months. The 3-year progression-free survival rate was 100%. Data on 5-year overall survival will be reported later. Conclusions: Although complete tumor regression was not achieved, immunotherapy with nivolumab and ipilimumab led to significant and durable tumor shrinkage in two-thirds of T1aN0M0 RCC patients, with minimal toxicity, making it a viable option for patients with significant comorbidities. Further data on long-term survival are awaited. Clinical trial information: NCT04134182 .
Real-world comparison of cost and adherence between patients receiving low-dose versus standard-dose abiraterone acetate (AA) in a safety-net hospital.
54 Background: While the standard dose of AA (1,000 mg) is taken on an empty stomach, low-dose AA (250 mg with a low-fat meal) is also an option, with both listed as standard of care in national guidelines for the treatment of prostate cancer (PCa). We sought to evaluate the cost and adherence of low-dose AA (LDAA) versus standard-dose AA (SDAA) in a diverse population treated at the University of Illinois Chicago (UIC), a Chicago safety-net hospital. Methods: PCa patients treated at UIC who filled at least oneprescription for AA between April 2017 and September 2024 were identified retrospectively. Key data such as age, race, ethnicity, insurance status, disease stage, monthly copays, medication fill history, dates of disease progression or death, and adverse events were obtained. Chi square analysis was used to compare cost, adherence, progression-free survival (PFS), and adverse events between the two groups. Adherence was calculated as the number of 30-day fills divided by the number of months the patient was prescribed AA, expressed as a percentage. Results: We identified 138 patients who filled a prescription for AA during the study timeframe (Table). 72.5% were Black, 55.1% had Medicare as their primary insurance, and 35.5% had Medicaid as their primary insurance. 26.8% had localized disease upon starting AA while 73.2% had metastatic disease (Table 1). Patients receiving LDAA were less likely to have a monthly copay of $100 or greater at any point compared to those receiving SDAA (7.3% vs. 19.6%, p=0.04). The percentage of patients with less than 80% adherence was 4.9% for those receiving LDAA compared to 10.7% of those receiving SDAA, however this difference did not meet statistical significance (p=0.20). Adverse events were similar in both cohorts, with 13.4% of those receiving LDAA having discontinued the medication due to toxicities compared to 10.7% of those receiving SDAA (p=0.64). Median PFS was 23 months in the standard-dose group but was not reached in the low-dose group due to data immaturity. Conclusions: Patients receiving LDAA experienced lower financial burden than those receiving SDAA, as quantified by copays of $100 or greater. There was not a statistically significant difference between the two groups in adherence or rate of adverse events requiring discontinuation. Data on the impact of dose and clinical outcomes are ongoing and maturing. LDAA (n=82, median age 65) SDAA (n=56, median age 68) Total (n=138, median age 66) Medicare 42 (51.2%) 34 (60.7%) 76 (55.1%) Medicaid 32 (39.0%) 17 (30.4%) 49 (35.5%) Private or other insurance 8 (9.8%) 5 (8.9%) 13 (9.4%) Black, non-Hispanic 59 (72.0%) 41 (73.2%) 100 (72.5%) White, non-Hispanic 7 (8.5%) 8 (14.3%) 15 (10.9%) Hispanic of any race 14 (17.1%) 7 (12.5%) 21 (15.2%) Other race 2 (2.4%) 0 (0%) 2 (1.4%) Localized disease 27 (32.9%) 10 (17.9%) 37 (26.8%) Metastatic disease 55 (67.1%) 46 (82.1%) 101 (73.2%)
Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line (1L) treatment in patients (pts) with homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.
LBA141 Background: Approximately one-quarter of advanced prostate cancers have alterations in DNA damage response genes directly or indirectly involved with HRR that can sensitize them to treatment with poly(ADP-ribose) polymerase inhibitors. The Phase 3 TALAPRO-2 trial met its primary endpoint, showing improved radiographic progression-free survival (rPFS) for TALA + ENZA vs placebo (PBO) + ENZA as 1L treatment in pts with mCRPC in the HRR-deficient cohort (cohort 2). At the first interim analysis, immature OS data favored TALA + ENZA vs PBO + ENZA. Here we report final OS data, a descriptive update of rPFS, and extended safety follow-up in cohort 2. Methods: Pts with HRR-deficient tumors were randomized 1:1 to ENZA 160 mg + either TALA 0.5 mg (0.35 mg if moderate renal impairment) or PBO once daily and stratified by prior abiraterone or docetaxel (yes/no) for castration-sensitive PC. Key eligibility criteria included asymptomatic or mildly symptomatic mCRPC, ECOG PS ≤1, ongoing androgen deprivation therapy, and no prior life-prolonging therapy for CRPC. The primary endpoint was rPFS by blinded independent central review. OS was an alpha-protected key secondary endpoint. To achieve statistical significance at the final OS analysis, the stratified log-rank 2-sided P value needed to be ≤0.024 using a group sequential design with O’Brien-Fleming spending function. Results: Overall, 399 pts were randomized (N=200, TALA + ENZA; N=199, PBO + ENZA). At data cutoff (Sept 3, 2024), 93 pts (46%) in the TALA + ENZA arm and 126 pts (63%) in the PBO + ENZA arm had died; median follow-up was 44.2 and 44.4 months, respectively. Hazard ratio (HR) for OS with TALA + ENZA vs PBO + ENZA was 0.622 (95% CI, 0.475–0.814; 2-sided P =0.0005); median OS (95% CI), 45.1 months (35.4–not reached) vs 31.1 months (27.3–35.4 months), respectively. In exploratory analyses, OS favored TALA + ENZA vs PBO + ENZA in pts with BRCA1/2 alterations (n=155; HR, 0.497; 95% CI, 0.318–0.776; P =0.0017) and pts without BRCA1/2 alterations (n=244; HR, 0.727; 95% CI, 0.516–1.024; P =0.0665). Updated rPFS data were consistent with the primary analysis, favoring the TALA + ENZA vs PBO + ENZA arm (HR, 0.468; 95% CI, 0.359–0.612; P <0.0001); median rPFS, 30.7 vs 12.3 months, respectively. Consistent with primary results, the most common grade 3–4 TEAEs with TALA + ENZA were anemia (43%) and neutropenia (20%). TEAEs were generally manageable; 26 pts (13%) discontinued TALA due to TEAEs. Conclusions: TALA + ENZA demonstrated a statistically significant and clinically meaningful improvement in OS vs ENZA. These data establish TALA + ENZA as a standard of care for 1L treatment in pts with HRR-deficient mCRPC. rPFS continued to favor TALA + ENZA. Safety was consistent with previous reports; no new safety signals were identified. Clinical trial information: NCT03395197 .
Deciphering immune-genomic markers of hyperprogression in patients (Pts) with metastatic urothelial cancer (mUC) treated with immune checkpoint inhibitors (ICIs).
840 Background: ICIs offer modest response rates (~20%) in mUC and there remains a critical need for validated biomarkers to predict patient benefit. Hyperprogressive disease (HPD), characterized by rapid tumor progression following ICI initiation, is a poorly understood phenomenon in mUC. No robust biomarkers currently exist to identify patients at risk for HPD, a condition that leads to unnecessary treatment and exacerbated toxicity. While patient factors associated with HPD have been studied, little is known about the tumor’s immune-genomic landscape in these cases. We investigate the immune-genomic features of mUC tumors associated with HPD to better understand and predict this response to ICI. Methods: We retrospectively analyzed 132 pts with mUC treated with atezolizumab or pembrolizumab between 2015-2023. All patients received at least 2 ICI cycles, and archival FFPE tumor samples were available for immune-genomic analysis. Pts were classified as responders (N=75, defined as complete/partial response or stable disease) or non-responders (N=57, progressive disease). HPD was defined as progression per RECIST within 14 weeks of ICI initiation. RNA was extracted from macrodissected FFPE samples, and transcriptomic profiling was performed using the Nanostring PanCancer IO 360 panel. Data were processed using nSolver 4.0 and nanostring data analysis service analyzed for differential gene expression. Receiver operator characteristic (ROC) analysis was conducted to assess the predictive power of immune signatures for HPD. Results: Of the 132 pts, 48 (36%) were classified as having HPD. Compared to non-responders without HPD, HPD tumors exhibited significant downregulation of immune signatures, including IFN Gamma, PD-L1, myeloid cells, and tumor inflammation signatures (TIS). Key chemokines and IFN downstream signaling were also downregulated (p-adj = 0.041). Single-gene analysis highlighted downregulation of CCL4 (logFC = -0.947, p = 0.00012), GBP1 (logFC = -0.8105, p = 0.00017), and NECTIN2 (logFC = -0.4792, p = 0.00032) in HPD tumors, though statistical significance was not reached after adjustment. ROC analysis demonstrated modest predictive power for HPD with AUCs of 0.66 for TIS and IFN Gamma, and 0.658 for the immunoproteasome. Conclusions: Our findings reveal a distinct immune-genomic profile in mUC tumors associated with HPD following ICI treatment, including reduced IFN Gamma, TIS, and myeloid cell signaling. These immune signatures may serve as potential biomarkers to identify pts at risk of HPD, warranting further validation in prospective trials. Ongoing analyses will continue to explore the genomic underpinnings of HPD and therapeutic resistance in mUC.
Design and modeling of a nanocomposite system for demineralization of sweet whey
Real-time detection of loosening torque in bolted joints using piezoresistive pressure-sensitive layer based on multi-walled carbon nanotubes reinforced epoxy nanocomposites
Abstract Bolted connections are extensively used in construction and machine design, playing critical roles in various industrial applications. Bolts and screws are, however, prone to loosening or separating due to factors such as shock, vibration, and temperature fluctuations. This self-loosening phenomenon poses a considerable challenge to the reliability of bolted connections, necessitating regular inspections to ensure their safety. In this study, we report a cost-effective technique for monitoring bolted joint loosening torque: BoltWISE (Bolt loosening detection with innovative sensors). BoltWISE employs an innovative sensor element consisting of a piezoresistive, pressure-sensitive layer made from multi-walled carbon nanotube/epoxy nanocomposites coated onto an FR4 substrate, functioning as a washer. Our approach provides high sensitivity, durability, linearity, and fast response times, with minimal hysteresis during both the tightening and loosening processes. Finite-element method simulations were conducted to determine the optimal sensor positions, ensuring fast response during bolt tightening and loosening. Our findings highlight BoltWISE as a promising, low-cost solution for efficiently detecting bolt loosening in industrial environments. Its ease of implementation and fabrication make it a valuable tool for improving safety and maintenance practices across various industries.